Interações de Sunitinibe
Sunitinibe (Sutent) tem 271 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 3; moderadas: 267; leves: 1; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.
Interações segundo a bula
Interações graves (3)
- BevacizumabeGrave
Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of SUTENT as monotherapy and administered in combination with bevacizumab. (bula de Sunitinibe, Advertências e precauções)
Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-emtansine Vinca alkaloids Not recommended during and 2 weeks after TOLSURA treatment. (bula de Itraconazol, Interações medicamentosas)
Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of voriconazole. (bula de Voriconazol, Interações medicamentosas)
Interações moderadas (267)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (bula de Sunitinibe, Advertências e precauções)
• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
- TensirolimoModerada
Concomitant use of TORISEL with sunitinib The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. (bula de Tensirolimo, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (bula de Sunitinibe, Advertências e precauções)
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)
Menções leves (1)
- AxitinibeLeve
MACE occurred in 7% of patients with advanced RCC treated with INLYTA in combination with avelumab compared to 3.4% treated with sunitinib in a randomized trial, JAVELIN Renal 101. (bula de Axitinibe, Advertências e precauções)
Verifique Sunitinibe com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.
Abrir no verificadorNão é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.